Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million.

Following on from the wonderful It Takes Two, developer Hazelight took things to the next level when it comes to scale in Split Fiction and continued to hone its craft as the modern-day masters of the ...

Jeremy has more than 2200 published articles on Collider to his name, and has been writing for the site since February 2022. He's an omnivore when it comes to his movie-watching diet, so will gladly ...

Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...

Noninferiority trial favored amiloride as an alternative to spironolactone in lowering home systolic blood pressure (SBP) for people with resistant hypertension. Twelve weeks into the trial, mean home ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat safely lowered 24-hour systolic BP compared with placebo in a phase 2 trial. A ...

Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, China Multiple studies have shown that finerenone (BAY 94-8862), a third-generation non-steroidal mineralocorticoid ...